On November 27, Nature published the results of an innovative breast cancer research project from the Netherlands. This study, the SONIA trial, showed that delaying and shortening the duration of a specific anti-cancer therapy (CDK4/6 inhibitors) in patients with hormone receptor-positive advanced breast cancer leads to similar survival outcomes, while reducing toxicity and achieving substantial cost reductions: over 45 million euros per year in the Netherlands and over 5 billion dollars in the United States.
Medical Xpress – latest medical and health news stories